



Assembly Biosciences Announces November Conference Participation

October 31, 2018

SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at various upcoming conferences in November, in addition to its presentation at AASLD on November 11, 2018 in San Francisco.

- **China Renaissance 6th Healthcare and Lifesciences Leadership Summit** – Shanghai, China
Presenter:Derek Small, President and Chief Executive Officer
Date: November 1-2, 2018
- **International HBV Cure Workshop** – Toronto, ON
Presenter:Richard Colonno, PhD, Executive Vice President, Chief Scientific Officer of Virology Operations
Date: November 7, 2018
- **Stanford Medicine Symposium on HBV and HDV** – Foster City, CA
Presenter:Uri Lopatin, MD, Chief Medical Officer
Date: November 8, 2018
- **Jefferies London Healthcare Conference** – London, UK
Presenter:Richard Colonno, PhD, Executive Vice President, Chief Scientific Officer of Virology Operations
Date:November 14-15, 2018

The scientific presentations will focus on targeting HBV core protein to clear infection with the goal of achieving higher cure rates in patients with chronic HBV.

A webcast of the Jefferies presentation will be available in the Events and Presentations section of the Company's website at www.assemblybio.com.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live synthetic biotherapeutic candidates with Assembly's fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL[®] delivery technology. For more information, visit assemblybio.com.

Forward-Looking Statements

The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of core inhibitors. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as "goal" and "potential." Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading "Risk Factors" in Assembly's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed with the Securities and Exchange Commission. Except as required by law, Assembly assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Assembly Biosciences, Inc.

Investors:

Lauren Glaser

(415) 521-3828

lglaser@assemblybio.com



Source: Assembly Biosciences, Inc.